Congress is considering a bill that would let patents on prescription drugs be rendered unenforceable over an honest paperwork error, even when the underlying invention is genuinely new, non-obvious, and valuable to patients. Supporters of the Medication Affordability and Patent Integrity Act (S. 2658), which the Senate Health, Education, Labor, and Pensions Committee reported in July, say it will lower drug prices by closing what they describe as a loophole that drugmakers use to extend their monopolies.
The U.S. Supreme Court issued an order on Monday in BMG Rights Management (US) LLC v. Vetter affirming the U.S. Court of Appeals for the Fifth Circuit’s judgment granting a songwriter ownership of the worldwide copyright in “Double Shot (Of My Baby’s Love).” The Court entered the affirmance under 28 U.S.C. Section 2109, following a September 30 reply in which BMG Rights Management (US) LLC and the other petitioners urged the Court to grant certiorari and reverse.
Venable LLP’s Intellectual Property Group is seeking a mid-level associate with five to seven years of substantive U.S. trademark experience in a law firm setting to join our practice in Washington, D.C. Our team advises and represents clients across the full spectrum of trademark and brand protection law, including prosecution, clearance, enforcement, portfolio management, and proceedings before the Trademark Trial and Appeal Board (TTAB).
Artificial intelligence could help deliver the next generation of lifesaving medicines. It could also weaken the economic foundation that makes discovering those medicines possible. Both propositions deserve serious attention, and neither is mutually exclusive. Celebrating faster discovery tells only part of the story if the same technology allows competitors to appropriate the commercial opportunity created by pioneer research or obtain patent claims that obstruct the innovator’s next steps.
This week on IPWatchdog Unleashed, I speak with Martin Correa. Correa, who leads foresight work at the World Intellectual Property Organization (WIPO). Correa’s job is not to predict the future of IP, but to consider what futures are possible so WIPO and Member States can be better prepared for whatever eventuality does materialize. And since there is no data about the future—as he puts it—his work uses signals of change, horizon scanning and competing scenarios to expose assumptions and identify the decisions that could push the IP system in one direction or another.
A patent’s economic value and the price it commands in a licensing negotiation can be very different things. The technology may deliver substantial commercial benefits, yet the amount a patent owner can capture depends on legal risk, enforcement costs, negotiating leverage, and each party’s business objectives. This week on IPWatchdog Unleashed, we ask how much a patent is really worth, and how to prove it at a negotiating table or in court. This conversation, which occurred as part of IPWatchdog’s 2026 Women’s IP Forum, examines how sophisticated licensors, licensees, counsel, and valuation professionals assess patent value in real-world transactions and disputes. The conversation explored royalty structures, comparable licenses, portfolio strength, litigation and validity risk, damages principles, standard-essential patent (SEP) licensing, and the practical factors that drive parties toward—or away from—a deal.
This week on IPWatchdog Unleashed, I speak with Nancy Braman. Recorded before a live audience at IPWatchdog’s 2026 Women’s IP Forum, our conversation explores how practitioners create opportunities, develop professional relationships, and build the skills necessary to succeed in patent law. From taking PLI patent bar review course before law school, to attending Franklin Pierce Law School, to spending more than three years writing and researching for IPWatchdog and now litigating high-stakes patent and intellectual property disputes for life sciences and technology companies. She has already had quite the journey, and I sense it is really just beginning.
On Monday, the U.S. Supreme Court issued an order list that included a denial of Google’s petition for writ of certiorari challenging the U.S. Patent and Trademark Office’s (USPTO’s) development of settled expectations doctrine at the Patent Trial and Appeal Board (PTAB). This latest setback to industry-wide efforts opposing the duration of a patent’s life in force as a consideration leading to discretionary denials of inter partes review (IPR) proceedings comes a few weeks after the U.S. Solicitor General urged denial of Google’s cert petition, agreeing with the Federal Circuit that such a challenge was not available on mandamus review.
The U.S. Supreme Court on Monday denied certiorari in Frederick L. Allen, et al. v. Joshua Stein, Governor of North Carolina, a decade-plus long case that led to a Supreme Court decision as well as the introduction and subsequent repeal of a law to shield North Carolina from copyright liability. In January 2026, the U.S. Court of Appeals for the Fourth Circuit issued the most recent ruling in the case, which related to Frederick (“Rick) Allen’s copyright battle against the State of North Carolina over documentary footage of a state-sponsored salvage project exhuming a shipwreck associated with the famed pirate, Blackbeard. Videographer Frederick Allen and his company Nautilus Productions recorded footage of a private company’s project to salvage Blackbeard’s flagship Queen Anne’s Revenge from the North Carolina coastline.
A patent’s economic value and the price it commands in a licensing negotiation can be very different things. The technology may deliver substantial commercial benefits, yet the amount a patent owner can capture depends on legal risk, enforcement costs, negotiating leverage, and each party’s business objectives. This week on IPWatchdog Unleashed, we ask how much a patent is really worth, and how to prove it at a negotiating table or in court. This conversation, which occurred as part of IPWatchdog’s 2026 Women’s IP Forum, examines how sophisticated licensors, licensees, counsel, and valuation professionals assess patent value in real-world transactions and disputes. The conversation explored royalty structures, comparable licenses, portfolio strength, litigation and validity risk, damages principles, standard-essential patent (SEP) licensing, and the practical factors that drive parties toward—or away from—a deal.
This week on IPWatchdog Unleashed, IPWatchdog President Renée C. Quinn spoke with Coke Morgan Stewart. Formerly Acting Director and Deputy Director of the U.S. Patent and Trademark Office (USPTO), Stewart is now president and CEO of the Council for Innovation Promotion (C4IP). Their conversation, recorded at IPWatchdog’s 2026 Women’s IP Forum, examines what she learned while leading the agency, why she believes the patent system needs legislative reform, and how her experience has shaped her approach to leadership and advocacy.
This week on IPWatchdog Unleashed, I spoke with Fran Cruz and Marlene Valderrama. Recorded before a live audience following IPWatchdog’s Women’s IP Forum, our conversation explored how professionals build relationships that lead to business, career opportunities, and better ways of doing their jobs. Drawing on their perspectives at Juristat and Halliburton, respectively, Fran and Marlene returned to a fundamental point: earning someone’s attention begins with understanding what matters to them. That requires asking questions and actually listening.
This week on IPWatchdog Unleashed, I spoke with Steve Caltrider, Vice President and Chief Intellectual Property Officer at Dana-Farber Cancer Institute, and a former General Patent Counsel at Eli Lilly. The discussion also examined patent quality and the role of examination. Caltrider’s view is that the best time to establish confidence in a patent is when the USPTO examines it—not years later through PTAB review or district court litigation, after investment decisions have already been made. He recognized the need for an error-correction mechanism, while cautioning that review should not become so extensive or unpredictable that it undermines the value of issued patents.
This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.
Get Email Updates